Another phase 1 study, NCT04117087, is studying the effect of a pooled long peptide vaccine targeting mutant KRAS co-administered with the immune checkpoint inhibitors nivolumab and ipilimumab in resected PDAC patients post adjuvant or neoadjuvant treatment, and in metastatic mismatch-repair-proficient colorectal cancer patients [43]. Here, KRAS is linked to colorectal cancer.